Thymic Carcinoma Clinical Trials 2024

What are the top hospitals conducting thymic carcinoma research?

In the realm of clinical trials for thymic carcinoma, several hospitals are leading the charge in research and innovation. The National Institutes of Health (NIH) Clinical Center in Bethesda stands out as a frontrunner with four ongoing trials dedicated to this rare cancer type. Over the years, they have conducted a total of five thymic carcinoma trials since their first recorded trial in 2011. Another institution making significant contributions is the renowned Memorial Sloan Kettering Cancer Center in New york, where two active clinical trials focusing on thymic carcinoma are currently underway. With a history dating back to their inaugural trial in 2009, they have completed three studies pertaining to this condition.

Notably located at 9000 Rockville Pike in Bethesda, another branch of NIH's Clinical Center has also made its mark with two active thymic carcinoma trials and an impressive record of eight previously conducted studies since initiating research on this cancer type back in 2007. Duke University Hospital located in Durham makes its presence known as well by actively participating in one current thymic carcinoma trial—their sole endeavor thus far into researching this particular cancer which started just last year-2022.

Last but not least is Cedars-Sinai Medical Center situated within Tarzana that contributes significantly despite being involved primarily through one active study regarding thymic carcinomas only recently due to commence during 2022; however it still adds commendably to scientific advancements with its previous single accomplished investigation over time.

These hospitals' dedication and commitment highlight the importance given towards understanding and treating such an uncommon form of cancer like thymic carcinoma. Their collective efforts demonstrate that even small-scale progress can yield substantial outcomes when it comes to unlocking breakthroughs and offering hope for those affected by these lesser-known conditions.

Which are the best cities for thymic carcinoma clinical trials?

When it comes to thymic carcinoma clinical trials, several cities emerge as prominent hubs for research and advancements. Bethesda, Maryland leads the way with six active trials investigating treatments like F/ Not Otherwise Specified (NOS), PT-112, and M7824. New york, New York follows closely behind with five ongoing studies that explore interventions such as Robotic-Assisted Surgery, VMD-928 300 mg Tablet, Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide. Houston, Texas also plays a significant role in thymic carcinoma research with four active trials focusing on various interventions including Robotic-Assisted Surgery and Magnetic Resonance Imaging. These cities are joined by Durham in North carolina and Tarzana in California where one trial each is underway investigating treatment options like Robotic-Assisted Surgery. Together these locations offer individuals battling thymic carcinoma access to cutting-edge clinical trials that hold promise for improved outcomes and future breakthroughs.

Which are the top treatments for thymic carcinoma being explored in clinical trials?

Clinical trials are paving the way for advancements in thymic carcinoma treatment, spotlighting several promising approaches. Robotic-assisted surgery is gaining attention with its precision and minimally invasive nature. PT-112 offers a potential breakthrough with its targeted therapy approach. M7824 shows promise as an immunotherapy option specifically designed to combat thymic carcinoma. Additionally, home-based cardiac rehabilitation aims to improve patient outcomes by providing support in the comfort of their own homes. Magnetic resonance imaging continues to play a vital role in diagnosis and monitoring throughout the treatment journey for individuals with thymic carcinoma. These innovative treatments hold great potential for improving outcomes and quality of life for patients battling this rare form of cancer.

What are the most recent clinical trials for thymic carcinoma?

Exciting developments have emerged in the realm of thymic carcinoma, as recent clinical trials shed light on potential treatment options. KFA115, a single-agent therapy, is currently undergoing Phase 1 trials for patients with this rare cancer type. Additionally, PT-112 and M7824 are showing promise in Phase 2 studies for thymic carcinoma treatment. These advancements provide hope for improved outcomes and enhanced quality of life for individuals battling thymic carcinoma. Nivolumab and pembrolizumab have also shown potential benefits in early-phase trials, highlighting their role as immunotherapy options worth exploring further. With ongoing research efforts like these, new horizons are opening up in the fight against thymic carcinoma.

What thymic carcinoma clinical trials were recently completed?

Recently completed clinical trials in the field of thymic carcinoma offer promising insights into potential treatments for this rare cancer. In December 2019, Nagla Abdel Karim concluded a trial investigating the efficacy of Bosutinib in combating thymic carcinoma. Furthermore, Xencor, Inc. wrapped up their trial on XmAb20717 therapy back in July 2018. These significant milestones contribute to our understanding of treatment options and provide hope for patients battling thymic carcinoma.